​

Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$14.81

52W Range

$6.83 - $16.54

50D Avg

$14.78

200D Avg

$12.50

Market Cap

$1.91B

Avg Vol (3M)

$997.45K

Beta

1.59

Div Yield

-

AUPH Company Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

130

IPO Date

Sep 03, 2014

Website

AUPH Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Product$271.35M$216.19M$158.53M
License, Collaboration and Royalty Revenue$11.71M$18.95M$16.98M

Fiscal year ends in Dec 25 | Currency in USD

AUPH Financial Summary

Dec 25Dec 24Dec 23
Revenue$283.06M$235.13M$175.51M
Operating Income$104.91M$-4.69M$-91.69M
Net Income$287.20M$5.75M$-78.02M
EBITDA$104.91M$31.73M$-63.05M
Basic EPS$2.14$0.04$-0.54
Diluted EPS$2.07$0.04$-0.54

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 26, 26 | 8:30 AM
Q3 25Nov 04, 25 | 8:30 AM
Q2 25Jul 31, 25 | 8:30 AM

Peer Comparison

TickerCompany
NUVBNuvation Bio Inc.
ABCLAbCellera Biologics Inc.
BHVNBiohaven Ltd.
IMCRImmunocore Holdings plc
STOKStoke Therapeutics, Inc.
CLDXCelldex Therapeutics, Inc.
VERAVera Therapeutics, Inc.
MNKDMannKind Corporation
JANXJanux Therapeutics, Inc.
HRMYHarmony Biosciences Holdings, Inc.